Spots Global Cancer Trial Database for pegylated liposomal doxorubicin
Every month we try and update this database with for pegylated liposomal doxorubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies | NCT00703170 | Resistant Solid... | Temsirolimus Pegylated lipos... | 18 Years - | Washington University School of Medicine | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | NCT03952572 | Peripheral T-ce... | Cyclophosphamid... pegylated lipos... Vincristine Prednisone Doxorubicin | 18 Years - 75 Years | Peking University | |
| A Study of ZN-c3 in Patients With Ovarian Cancer | NCT04516447 | Solid Tumor Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | ZN-c3 Carboplatin Pegylated lipos... Paclitaxel Gemcitabine Bevacizumab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) | NCT00779285 | Breast Neoplasm | Pegylated Lipos... | 18 Years - | Merck Sharp & Dohme LLC | |
| Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum | NCT05512676 | Ovarian Neoplas... Chemotherapeuti... Chemotherapy Ef... Chemotherapy-in... Chemotherapy-in... | 18 Years - 80 Years | Oslo University Hospital | ||
| A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | NCT00687440 | Breast Neoplasm | Pegylated Lipos... Docetaxel Trastuzumab | 18 Years - 70 Years | Merck Sharp & Dohme LLC | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | NCT03994107 | Breast Cancer | Pegylated Lipos... Albumin-bound p... Trastuzumab | 18 Years - 70 Years | Peking Union Medical College | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | NCT03467178 | Recurrent, Plat... | Decitabine Carboplatin Pegylated Lipos... Gemcitabine Paclitaxel | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | NCT01358071 | Ovarian Cancer | NGR-hTNF Pegylated lipos... Doxorubicin | 18 Years - | AGC Biologics S.p.A. | |
| R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | NCT02428751 | Lymphoma, Large... | Pegylated lipos... Doxorubicin Rituximab Cyclophophamide Vincristine Prednisone | 60 Years - 80 Years | Sun Yat-sen University | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | NCT01113957 | Ovarian Cancer | ABT-888 pegylated lipos... temozolomide | 18 Years - 99 Years | AbbVie | |
| Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer | NCT01051362 | Non-small Cell ... | PLD and Carbopl... | 18 Years - 85 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | NCT00687440 | Breast Neoplasm | Pegylated Lipos... Docetaxel Trastuzumab | 18 Years - 70 Years | Merck Sharp & Dohme LLC | |
| Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | NCT03335241 | Ovarian Cancer | Fludarabine and... Pegylated lipos... | 18 Years - 70 Years | Sun Yat-sen University | |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | NCT02903004 | Ovarian Neoplas... | Trabectedin Pegylated Lipos... Topotecan Gemcitabine Weekly Paclitax... Carboplatin | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | NCT00706953 | Multiple Myelom... | bortezomib; peg... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | NCT04765228 | Stage III Adult... | Pegylated lipos... Anlotinib | 14 Years - 75 Years | Fudan University | |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | NCT00780039 | Ovarian Neoplas... | Pegylated Lipos... Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | NCT03804866 | Ovarian Cancer | NGR-hTNF Pegylated lipos... Doxorubicin | 18 Years - | AGC Biologics S.p.A. | |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | NCT00780039 | Ovarian Neoplas... | Pegylated Lipos... Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | NCT03161132 | Advanced Ovaria... | Olaparib Pegylated Lipos... | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | NCT06014528 | Ovarian Cancer ... | IN10018 Placebo of IN10... Pegylated Lipos... | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer | NCT05976932 | Ovarian Cancer | pegylated lipos... | 18 Years - | Fudan University | |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | NCT06072781 | Low Grade Serou... | avutometinib Defactinib Pegylated lipos... Paclitaxel Topotecan Letrozole Anastrozole | 18 Years - | Verastem, Inc. | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy | NCT02953184 | Antineoplastic ... | Pegylated Lipos... Cyclophosphamid... Taxotere Dexrazoxane (DZ... vitamin B Doxorubicin Breast Conserve... Modified Radica... Sentinel Lymph ... | 18 Years - 70 Years | Jilin University | |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | NCT01227941 | Ovarian Cancer | MK-4827 + pegyl... MK-4827 + pegyl... | 18 Years - | Tesaro, Inc. | |
| Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | NCT00610792 | Ovarian Cancer | bortezomib pegylated lipos... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | NCT03123770 | Breast Cancer | Pegylated lipos... Cyclophosphamid... Epirubicin Docetaxel | 18 Years - 70 Years | Zhejiang University | |
| Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer | NCT00524810 | Metastatic Brea... | Pegylated lipos... Docetaxel | 18 Years - | ARCAGY/ GINECO GROUP | |
| Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma | NCT03342300 | Progression-fre... Overall Surviva... Toxicity | pegylated lipos... pirarubicin | 16 Years - | Peking University People's Hospital | |
| Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | NCT03123770 | Breast Cancer | Pegylated lipos... Cyclophosphamid... Epirubicin Docetaxel | 18 Years - 70 Years | Zhejiang University | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer | NCT06014528 | Ovarian Cancer ... | IN10018 Placebo of IN10... Pegylated Lipos... | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer | NCT03794778 | Efficacy and Sa... | pegylated lipos... paclitaxel Carboplatin | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer | NCT01051362 | Non-small Cell ... | PLD and Carbopl... | 18 Years - 85 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse | NCT00189553 | Ovarian Cancer Fallopian Tube ... | Pegylated lipos... Carboplatin Paclitaxel | 18 Years - | ARCAGY/ GINECO GROUP | |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | NCT00780039 | Ovarian Neoplas... | Pegylated Lipos... Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | NCT01279291 | Neoplasms Ovarian Neoplas... Fallopian Tube ... Primary Periton... | KHK2866 Gemcitabine and... paclitaxel pegylated lipos... | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | NCT00861120 | Epithelial Ovar... | Pegylated lipos... Panitumumab | 18 Years - | Vejle Hospital | |
| Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients | NCT00128778 | Breast Neoplasm... | Pegylated lipos... | 18 Years - 90 Years | Spanish Breast Cancer Research Group | |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | NCT01227941 | Ovarian Cancer | MK-4827 + pegyl... MK-4827 + pegyl... | 18 Years - | Tesaro, Inc. | |
| A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | NCT01113957 | Ovarian Cancer | ABT-888 pegylated lipos... temozolomide | 18 Years - 99 Years | AbbVie | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | NCT00303108 | Metastatic Brea... | Pegylated lipos... Carboplatin trastuzumab | 18 Years - | US Oncology Research | |
| A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients | NCT01210768 | Breast Cancer | Epirubicin+Cycl... liposomal-doxor... | 20 Years - 70 Years | TTY Biopharm | |
| Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | NCT00610792 | Ovarian Cancer | bortezomib pegylated lipos... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | NCT03164993 | Cancer, Breast Triple Negative... | Atezolizumab Pegylated lipos... Cyclophosphamid... Placebo | 18 Years - | Oslo University Hospital | |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | NCT02431559 | Ovarian Cancer | Durvalumab Pegylated Lipos... Motolimod | 18 Years - | Ludwig Institute for Cancer Research | |
| To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | NCT05656079 | Breast Cancer | Pegylated lipos... Epirubicin Cyclophosphamid Trastuzumab Pertuzumab Docetaxel | 18 Years - 70 Years | Shanghai Pudong Hospital | |
| Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer | NCT03367182 | Ovarian Cancer | Weekly paclitax... Topotecan Pegylated lipos... Bevacizumab | 18 Years - | Yonsei University | |
| A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | NCT00736333 | Breast Neoplasm | Pegylated Lipos... | - | Merck Sharp & Dohme LLC | |
| Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | NCT00303108 | Metastatic Brea... | Pegylated lipos... Carboplatin trastuzumab | 18 Years - | US Oncology Research | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | NCT05870748 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... Platinum-resist... | Luveltamab taze... Pegfilgrastim Gemcitabine Paclitaxel Pegylated lipos... Topotecan | 18 Years - | Sutro Biopharma, Inc. | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | NCT03409198 | Breast Cancer Hormone Recepto... Metastatic Brea... | Ipilimumab Nivolumab Pegylated lipos... Cyclophosphamid... | 18 Years - | Oslo University Hospital | |
| Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | NCT01837251 | Recurrent Plati... | Carboplatin PLD Bevacizumab | 18 Years - | AGO Research GmbH | |
| Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | NCT03952572 | Peripheral T-ce... | Cyclophosphamid... pegylated lipos... Vincristine Prednisone Doxorubicin | 18 Years - 75 Years | Peking University | |
| Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | NCT01206881 | Breast Cancer | pegylated lipos... | 18 Years - 75 Years | Herlev Hospital | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma | NCT05411237 | Kaposi Sarcoma HIV-1-infection AIDS-related Ka... | Pegylated lipos... Paclitaxel | 18 Years - | AIDS Malignancy Consortium | |
| Metronomic PLD in Patients With Primary Endocrine Resistant ABC | NCT03071926 | Advanced Breast... | Pegylated Lipos... | 18 Years - 75 Years | Fudan University | |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | NCT05870748 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... Platinum-resist... | Luveltamab taze... Pegfilgrastim Gemcitabine Paclitaxel Pegylated lipos... Topotecan | 18 Years - | Sutro Biopharma, Inc. | |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | NCT02903004 | Ovarian Neoplas... | Trabectedin Pegylated Lipos... Topotecan Gemcitabine Weekly Paclitax... Carboplatin | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | NCT03164993 | Cancer, Breast Triple Negative... | Atezolizumab Pegylated lipos... Cyclophosphamid... Placebo | 18 Years - | Oslo University Hospital | |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. | |
| A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | NCT00736333 | Breast Neoplasm | Pegylated Lipos... | - | Merck Sharp & Dohme LLC | |
| The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma | NCT05774275 | High-Risk Local... | Pegylated Lipos... Doxorubicin Anti-PD-1 monoc... Radiotherapy | 18 Years - 75 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
